首页> 外文OA文献 >PCN99 Cost-Effectiveness of Dasatinib versus High-Dose Imatinib and Nilotinib in Patients with Chronic Myeloid Leukaemia Resistant to Standard-Dose Imatinib in Portugal

【2h】

PCN99 Cost-Effectiveness of Dasatinib versus High-Dose Imatinib and Nilotinib in Patients with Chronic Myeloid Leukaemia Resistant to Standard-Dose Imatinib in Portugal

机译：葡萄牙对标准剂量伊马替尼耐药的慢性粒细胞白血病患者，达沙替尼与大剂量伊马替尼和尼洛替尼的PCN99成本-效果

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Darba J.; Kaskens L.; Abecasis M.; Vitorino R.; Carrasco J.;
展开▼
作者单位

展开▼
年度 2011
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Are there better Bcr-Abl kinase inhibitors for chronic myeloid leukaemia than imatinib? Evaluation of Saglio G, Kim D-W, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010;362:2251-9, and Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010;362:2260-70. [J] . Doggrell SA, Christensen AM Expert opinion on pharmacotherapy . 2011,第1期

机译：是否有比伊马替尼更好的Bcr-Abl激酶抑制剂用于慢性粒细胞白血病？ Saglio G，Kim D-W，Issaragrisil S等的评估。尼洛替尼与伊马替尼治疗新诊断的慢性粒细胞白血病。 N Engl J Med 2010; 362：2251-9，and Kantarjian H，Shah NP，Hochhaus A等。达沙替尼与伊马替尼治疗新近诊断的慢性期慢性粒细胞白血病。 N Engl J Med 2010; 362：2260-70。
2. Comparative analyses of nilotinib versus high-dose imatinib versus sustained standard-dose imatinib in patients with chronic phase chronic myeloid leukemia following suboptimal molecular response to first-line imatinib [J] . Lee Sung-Eun, Choi Soo-Young, Kim Soo-Hyun, Leukemia Research: A Forum for Studies on Leukemia and Normal Hemopoiesis . 2018,第期

机译：少量分子反应对第一线伊马替尼的慢性分子慢性骨髓白血病患者中尼洛涅布对高剂量伊替尼与持续标准剂量伊替尼的比较分析
3. Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia: A systematic review and economic evaluation [J] . LovemanE., CooperK., BryantJ., Health technology assessment: HTA . 2012,第23期

机译：达沙替尼，大剂量伊马替尼和尼罗替尼治疗伊马替尼耐药的慢性粒细胞白血病：系统评价和经济评价
4. Development and validation of an UHPLC-MS/MS method to quantify imatinib, desmethylimatinib, dasatinib, nilotinib and ponatinib in dried plasma spots [C] . Alessandra Ariaudo, Marco Simiele, Fabio Favata, ASMS Conference on Mass Spectrometry and Allied Topics . 2016

机译：UHPLC-MS / MS方法的开发和验证量化伊马替尼，去甲基氨基啶，Dasatinib，尼洛尼布和Ponatinib在干等离子体斑点中的方法
5. Influences on physician recommendation for imatinib mesylate in chronic phase chronic myeloid leukemia patients. [D] . Iyer, Shrividya Sethuraman. 2003

机译：对慢性期慢性粒细胞白血病患者甲磺酸伊马替尼的医师推荐的影响。
6. Dasatinib high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia: a systematic review and economic evaluation. [O] . E Loveman, K Cooper, J Bryant, -1

机译：达沙替尼高剂量伊马替尼和尼罗替尼用于治疗伊马替尼耐药的慢性髓性白血病的系统评价和经济评价。
7. PCN13 Cost-Effectiveness Analysis of Nilotinib Versus Dasatinib in Patients With Imatinib-Resistant or Imatinib-Intolerant Chronic Myeloid Leukemia (CML) [O] . Niu X., Hay J. 2012

机译：尼洛替尼与达沙替尼对伊马替尼耐药或伊马替尼耐药的慢性粒细胞白血病（CML）患者的PCN13成本-效果分析

PCN99 Cost-Effectiveness of Dasatinib versus High-Dose Imatinib and Nilotinib in Patients with Chronic Myeloid Leukaemia Resistant to Standard-Dose Imatinib in Portugal

著录项

引文网络

相似文献

相关主题

期刊订阅